Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

A compound, or a prodrug, tautomeric, pharmaceutically acceptable salt, or stereoisomeric form thereof, having a structure of Formula II:

• wherein
• B represents MnR8;
• Ar represents an aryl or heteroaryl ring;
• V represents O, S, or N—CN;
• W represents O, S, or NR″;
• R′ represents, independently for each occurrence, H, lower alkyl, or a metal counterion;
• R″ represents, independently for each occurrence, H or lower alkyl;
• R′″ represents H or optionally substituted lower alkyl;
• R5 represents Mn, JK;
• R6 represents H, OH, or MnQ;
• R7 represents H, halogen, hydroxyl, lower alkyl or lower alkoxyl;
• R8 represents substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, cyclo-alkyl, heterocyclyl, or amine;
• J represents C(═O), C(═S), or SO2;
• K represents OR′, N(R″)2, or N(R′)SO2R″;
• M, independently for each occurrence, represents a substituted or unsubstituted methylene group, NR″, O, S, S(O), or S(O2);
• n represents an integer from 1-7 when present in B, from 0-6 when present in R5, and from 1-3 when present in R6;
• and
• Q represents a substituted or unsubstituted:
• tertiary amino substituent or nitrogen-containing heterocycle.